Open Access
Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer
Molly Brewer1,James Ranger-Moore1,William Satterfield1,Zengping Hao1,Jian Wang1,Emily Brewer1,J Taylor Wharton1,Robert Bast1,Changping Zou1
Department of OB/GYN, University of Arizona, College of Medicine, Tucson, AZ 8572, USA.
DOI: 10.2741/2228 Volume 12 Issue 6, pp.2260-2268
Published: 01 January 2007
(This article belongs to the Special Issue Cancer chemoprevention - 1)

4-(N-hydroxyphenyl) retinamide (4-HPR) and the oral contraceptives (OCP) are currently being used alone, and in combination, for the prevention of ovarian cancer. However, the mechanism of their effects has not been studied. Non-human primate models are ideal for studying the role of these and other drugs for cancer chemoprevention because of the genetic similarity between primates and humans in respect to hormone regulation and menstrual cycle. 4-HPR and OCP were administered to sixteen female adult Macacca mulatta (Rhesus macaques) for three months alone and in combination. Laparotomy was performed before and after treatment, and ovarian biopsies were obtained to evaluate the expression of retinoid and hormone receptors, and apoptosis. ER alpha was undetectable, but ER beta, PR, RXR alpha, and RXR gamma were constitutively expressed in the ovaries. 4-HPR induced RXR alpha and RXR gamma expression at a low level and, OCP induced expression of ER beta. However, the combination of 4-HPR with OCP had a larger effect on expression of retinoid receptors. Apoptosis was detected in the 4-HPR group (equivalent dose: 200 mg/day).

Share and Cite
Molly Brewer, James Ranger-Moore, William Satterfield, Zengping Hao, Jian Wang, Emily Brewer, J Taylor Wharton, Robert Bast, Changping Zou. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Frontiers in Bioscience-Landmark. 2007. 12(6); 2260-2268.